![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » APHIOS CORPORATION ANNOUNCES COLLABORATION WITH JAPANESE COMPANIES
APHIOS CORPORATION ANNOUNCES COLLABORATION WITH JAPANESE COMPANIES
July 20, 2005
Aphios Corporation today announced that it has entered a Research and Development collaboration with two Japanese companies, Bio Research Corporation of Yokohama, Yokohama, Japan and Tokyo Supply, Ltd., Minato, Japan to develop an orally-bioavailble anti-cancer therapaeutic. The collaborators plan to develop a water-soluble paclitaxel prodrug. The molecule is a combination of a paclitaxel molecule, the potent anticancer drug, and a sugar molecule that enhances solubility. This molecular combination is not bioactive prior to treatment and is significantly more water-soluble than paclitaxel. The water-soluble nature of this novel therapeutic allows for oral digestion rather than intra-venous (IV) injection.
Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1014635XSL_NEWSML_TO_NEWSML_WEB.xml)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct